◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › R › RYTM

Rhythm Pharmaceuticals Inc (RYTM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-14

Rhythm Pharmaceuticals Inc (RYTM) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 414 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, RYTM reported $190M in revenue and ($197M) in net income.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.

Interactive charts & full statements → Open the RYTM valuation workbench →

RYTM Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Total Revenue$239M$190M$130M$77M$24M$3M$0M$0M$0M$0M$0M$0M$0M——
Gross Profit$213M$170M$117M$68M$22M$3M($1M)($1M)$0M$0M$0M$0M$0M——
Gross Margin %89.1%89.7%89.7%88.0%91.0%81.0%-1971.4%————————
Operating Income (EBIT)($201M)($192M)($266M)($184M)($179M)($170M)($137M)($146M)($78M)($32M)($26M)($11M)($6M)($21M)($18M)
Operating Margin %-84.1%-101.2%-204.0%-238.1%-757.9%-5391.9%-390214.3%————————
Net Income($206M)($197M)($261M)($185M)($181M)($68M)($131M)($135M)($74M)($34M)($26M)($11M)($6M)($21M)($18M)
Net Margin %-86.2%-103.6%-200.3%-238.5%-766.2%-2156.2%-373505.7%————————
EBITDA($185M)($174M)($238M)($168M)($174M)($169M)($136M)($145M)($78M)($32M)($26M)($10M)—($21M)($18M)
Earnings Per Share (EPS)$-3.07$-3.02$-4.27$-3.20$-3.47$-1.37$-2.96$-3.70$-2.39$-1.26$-1.55$-1.09$-0.12$-0.43$-0.36
Shares Outstanding (M)69M65M61M58M52M50M44M36M31M27M17M10M—50M50M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RYTM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$71M$60M$57M$51M$49M$33M$42M$33M
Gross Profit$62M$53M$52M$46M$43M$29M$38M$29M
Gross Margin %87.5%88.1%91.6%89.3%88.6%88.8%91.0%88.5%
Operating Income (EBIT)($49M)($52M)($47M)($53M)($45M)($47M)($41M)($44M)
Operating Margin %-68.1%-87.1%-82.2%-102.6%-93.4%-143.7%-98.6%-132.0%
Net Income($49M)($56M)($48M)($53M)($47M)($49M)($43M)($44M)
Net Margin %-69.2%-92.6%-83.0%-103.1%-96.1%-151.3%-103.5%-131.2%
EBITDA($44M)($50M)($43M)($48M)($40M)($44M)($38M)($38M)
Earnings Per Share (EPS)$-0.72$-0.82$-0.71$-0.82$-0.73$-0.78$-0.70$-0.71
Shares Outstanding (M)69M68M67M64M64M63M62M61M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RYTM Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Cash from Operations (CFO)($105M)($116M)($114M)($136M)($173M)($146M)($122M)($123M)($62M)($29M)($23M)($7M)($8M)($19M)($18M)
Capital Expenditures (CapEx)$1M$1M$0M$0M$4M$5M$0M$3M$1M$0M$1M$0M$0M$0M$0M
Free Cash Flow (FCF)($106M)($117M)($114M)($136M)($178M)($151M)($122M)($126M)($63M)($30M)($24M)($7M)($8M)($19M)($18M)
FCF Margin %-44.4%-61.5%-87.5%-175.9%-751.8%-4801.4%-349125.7%————————
Dividends Paid—$5M$4M——————$0M—————

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RYTM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($9M)($44M)($25M)($27M)($23M)($40M)($19M)($25M)
Capital Expenditures (CapEx)$0M$0M$1M$0M$0M$0M$0M$40M
Free Cash Flow (FCF)($9M)($44M)($26M)($27M)($23M)($40M)($19M)($65M)
FCF Margin %-12.7%-73.5%-46.0%-51.9%-48.1%-123.4%-45.1%-196.1%
Dividends Paid——$0M$1M$3M——$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RYTM Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Total Assets$437M$480M$392M$333M$382M$330M$187M$309M$260M$152M$12M$37M$0M$18M$19M
Cash & Cash Equivalents$66M$54M$89M$60M$128M$59M$101M$62M$50M$34M$7M$35M$0M$7M$12M
Total Liabilities$220M$210M$228M$163M$118M$45M$21M$28M$14M$7M$5M$5M$1M$76M$55M
Total Debt (Short + Long-Term)$1M$1M$2M$1M$2M$1M$1M$0M$0M$0M$0M$4M$0M$0M$0M
Total Shareholders' Equity$217M$270M$165M$170M$264M$284M$167M$281M$246M$145M$7M$32M$0M($57M)($36M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RYTM viewer.

Other Companies in BIOTECHNOLOGY

← RYOJAll “R” companiesRYZ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.